



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 9, 2008.

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By: Deborah Barragan
Deborah Barragan

Appl. No. : 10/563,655 Confirmation No. 3991
Applicant : J. Christopher Anderson, et al.
Filed : January 5, 2006
TC/A.U. : 1652
Examiner : Gebreyesus, Kagne, H.

Docket No. : 54A-000410US
Customer No. : 22798

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the restriction requirement of April 9, 2008, Applicants elect group II (claims 17-26) and the species of SEQ ID NO: 15, with traverse.

The basis for the alleged lack of unity is an argument that Thorbjarnsdottir et al. anticipates claim 1. Applicants respectfully submit that this argument is incorrect, and that claims 1-26 do, in fact, share unity of invention.

Thorbjarnsdottir et al. describe the cloning of an amber suppressor allele of the *E. coli leuX (supP)* gene. Significantly, the Thorbjarnsdottir et al. tRNA gene is not orthogonal to the *E. coli cell*. There simply is no orthogonal tRNA or RS in Thorbjarnsdottir et al. This is in sharp contrast to the *claimed* invention, in which the relevant tRNA and RS are *orthogonal* to the system (cell or composition) at issue.

Thus, for example, many express working examples of the invention are *orthogonal* in *E. coli*., rather than being native or endemic to it, as are the tRNAs of Thorbjarnsdottir et al. (*i.e.*, the Thorbjarnsdottir tRNAs are from *E. coli* or bacteriophage).